Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 5,507 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo once daily Clear all
Active, not recruiting Phase 3 Interventional

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

NCT06373731
View directory record Official record
Conditions
Age Related Macular Degeneration (ARMD)
Interventions
Elamipretide, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
55 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
31
States / cities
Phoenix, Arizona • Sun City, Arizona • Huntington Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 28, 2026, 5:42 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

NCT01744496
View directory record Official record
Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Gilbert, Arizona • Sunnyvale, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 28, 2026, 5:42 PM EDT
Completed Not applicable Interventional

Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis

NCT01848327
View directory record Official record
Conditions
Relapsing Remitting MS, Secondary Progressive MS, Primary Progressive MS
Interventions
Caprylic Triglyceride, Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 59 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 28, 2026, 5:42 PM EDT
Not listed Phase 3 Interventional Results available

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

NCT00382070
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Placebo
Drug · Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
3,966 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2025
U.S. locations
777
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 523 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 28, 2026, 5:42 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

NCT05206773
View directory record Official record
Conditions
Fabry Disease
Interventions
Venglustat (GZ402671), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

NCT03547583
View directory record Official record
Conditions
Chronic Heart Failure With Preserved Ejection Fraction
Interventions
Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
29
States / cities
Beverly Hills, California • Carmichael, California • West Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 28, 2026, 5:42 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

NCT00694382
View directory record Official record
Conditions
Venous Thromboembolism, Cancer
Interventions
Semuloparin sodium, Placebo (for semuloparin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
48
States / cities
Birmingham, Alabama • Casa Grande, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 28, 2026, 5:42 PM EDT
Terminated Phase 2 Interventional

A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01579279
View directory record Official record
Conditions
Diabetic Neuropathic Pain
Interventions
ABT-652 6 mg, ABT-652 12 mg, ABT-652 12 mg - 18 mg, Placebo, Duloxetine
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Anaheim, California • Walnut Creek, California • Milford, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 28, 2026, 5:42 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Cannabis-Tobacco Co-Use Treatment Study

NCT06883162
View directory record Official record
Conditions
Tobacco Use Disorder, Tobacco Use Cessation, Cannabis Use, Cannabis Use Disorder, Marijuana Use
Interventions
Varenicline, Counseling, Psychosocial modules
Drug · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 28, 2026, 5:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

NCT02384941
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
63
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 28, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge

NCT01107405
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Loteprednol etabonate base (QD), Loteprednol etabonate base (BID), Loteprednol etabonate base (QID), Loteprednol etabonate suspension, Vehicle of loteprednol etabonate
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Oct 28, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

A Study in Adults and Adolescents With Angelman Syndrome (STARS)

NCT02996305
View directory record Official record
Conditions
Angelman Syndrome
Interventions
OV101 Regimen 1, OV101 regimen 2, Placebo
Drug · Other
Lead sponsor
Healx AI
Industry
Eligibility
13 Years to 49 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • San Diego, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 28, 2026, 5:42 PM EDT
Terminated Phase 3 Interventional

Efficacy of Ramelteon in Adults With Chronic Insomnia

NCT00672724
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
43
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 28, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT01151423
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Placebo
Biological
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 28, 2026, 5:42 PM EDT
Completed Phase 3 Interventional

HKT-500 in the Treatment of Adult Patients With Ankle Sprain

NCT00927641
View directory record Official record
Conditions
Ankle Sprain
Interventions
Ketoprofen Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 28, 2026, 5:42 PM EDT
Completed Phase 2 Interventional

AZD6765 Severe Major Depressive Disorder (MDD) IV

NCT00781742
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD6765, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
27
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 28, 2026, 5:42 PM EDT
Recruiting Not applicable Interventional

Maintenance rTMS for Depression (Maitr-De)

NCT06938841
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Transcranial Magnetic Stimulation (TMS) - Standard maintenance rTMS:, Transcranial Magnetic Stimulation (TMS) - Clustered maintenance rTMS:, Transcranial Magnetic Stimulation (TMS) -- Sham maintenance rTMS
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 28, 2026, 5:42 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

NCT00321984
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
153
States / cities
Alabaster, Alabama • Birmingham, Alabama • Hueytown, Alabama + 150 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 28, 2026, 5:42 PM EDT
Active, not recruiting Not applicable Interventional

Effects of Vitamin K on Lower-extremity Function in Adults With Osteoarthritis:

NCT05505552
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Vitamin K, Placebo
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
50 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 28, 2026, 5:42 PM EDT
Recruiting Phase 2 Interventional

Metformin for Fibromyalgia Symptoms (INFORM Trial)

NCT05900466
View directory record Official record
Conditions
Fibromyalgia Syndrome
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 28, 2026, 5:42 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin

NCT00947557
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Dutogliptin, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
98
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 28, 2026, 5:42 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

NCT03706365
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abemaciclib, Placebo, Abiraterone acetate, Prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 28, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT03118765
View directory record Official record
Conditions
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GSP304 (tiotropium bromide) Inhalation Solution, GSP304 Placebo Inhalation Solution, Spiriva® Respimat® inhalation spray
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
40 Years to 85 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
25
States / cities
Andalusia, Alabama • Phoenix, Arizona • Tempe, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 28, 2026, 5:42 PM EDT
Completed Phase 2 Interventional

Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis

NCT01452815
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Placebo, 10mg TZP-102, 20mg TZP-102
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Oct 28, 2026, 5:42 PM EDT